Early Warning System

# EIB-20190866

## OSE IMMUNOTHERAPEUTICS (EGFF) (COVID-19)

# Early Warning System

## OSE IMMUNOTHERAPEUTICS (EGFF) (COVID-19)

EIB-20190866

### Quick Facts

| | |
|---|---|
| **Countries** | France |
| **Financial Institutions** | European Investment Bank (EIB) |
| **Status** | Proposed |
| **Bank Risk Rating** | U |
| **Voting Date** | 2021-02-12 |
| **Borrower** | OSE IMMUNOTHERAPEUTICS SA |
| **Sectors** | Education and Health |
| **Investment Type(s)** | Loan |
| **Investment Amount (USD)** | $ 30.30 million |
| **Loan Amount (USD)** | $ 30.30 million |
| **Project Cost (USD)** | $ 71.51 million |

## Project Description

According to EIB website, the project will support the emergence of therapeutic solutions for various cancers and autoimmune diseases, some for which current treatments are not satisfactory (such as pancreatic cancer and ulcerative colitis), and others for which there currently are no treatment available. The company's pipeline includes an immunotherapy that is in Phase III clinical stage for the treatment of lung cancer, as well as in Phase II clinical trial to pancreatic cancer, a humanised monoclonal antibody that is in pre-clinical stage for the treatment of various cancers, a humanised monoclonal antibody that is in Phase I clinical trial for the treatment of inflammatory autoimmune diseases and a prophylactic vaccine against SARS-CoV-2, for which the clinical phase start is expected in Q1-2021.

## Investment Description

- European Investment Bank (EIB)

| Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
|---|---|---|---|---|---|---|
| - | - | - | - | OSE IMMUNOTHERAPEUTICS SA | Client | - |

### Contact Information

No contact information provided at the time of disclosure.

### ACCESS TO INFORMATION

You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm

### ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces